Editas Corp (EDIT) Cash Funds per Single Share

Corporate emblem and logo of Editas Medicine, Inc. (EDIT)

Quarterly cash per share dynamics for Editas Medicine, Inc. (EDIT) on GURU.Markets demonstrate the company's liquidity, where the value 1.23 represents the current metric. The business is protected by a sovereign innovation cycle that remains independent of macroeconomic trends. Revenues are based on partnership payments and royalties for CRISPR technologies. Results here are driven by scientific breakthroughs rather than market cyclicality, rendering the asset resilient.

EDIT Editas Medicine Inc: Cash per Single Share in the range 07/04/2022 - 11/21/2026

Analytical breakdowns for Editas Medicine, Inc.

- market value and analyst target forecast:
- cash position and cash flow details:
Summary company analysis:EDIT Editas Medicine, Inc.
Manufactured product of Editas Medicine Inc

Cash per share determines the intrinsic value of the security through the volume of liquid assets available per share of capital, serving as a safeguard against market overvaluation. By analyzing the cash per share history, an investor assesses the financial stability of Editas Medicine, Inc. (EDIT) during its strategic transition toward in-vivo technologies and IT licensing, distinguishing the actual margin of safety from price volatility.

Competing companies

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Cash per Share SLDB (Solid Biosciences Inc.)|Amount of Cash per Share OCGN|PacBio Corp - Cash per Share|Benitec Biopharma Inc. (BNTC) - Cash per Single Share|DSGN: Cash per Share|Cash Funds per Single Share RCKT|Cash per Single Share FDMT|Cash Funds per Single Share LXEO (Lexeo Therapeutics)|Cash per Share KRRO|SLN - Cash on Hand per Share|Cash per Share PRQR (ProQR)|CDXS - Cash per Single Share|Sangamo Therapeutics Inc. - Cash per Share|NAUT - Cash per Share|MGX: Cash per Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology